$FTH News

Needham Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $56

Faeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial Cancer

Faeth Therapeutics Says FDA Grants Fast Track Designation To Combination Of Sapanisertib And Serabelisib With Paclitaxel For Treatment Of Patients With Endometrial Cancer

Faeth Therapeutics Strengthens Executive Team with Senior Leadership Appointments

Faeth Therapeutics: PI3K Pathway Inhibitor With Key Data Catalyst In Play Intrigues

HC Wainwright & Co. Reiterates Buy on Faeth Therapeutics, Maintains $60 Price Target

Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Faeth Therapeutics to Present PK/PD Modeling That Informed PIKTOR Dose Selection in Ongoing FTH-PIK-201 Trial at Upcoming Scientific Conference

Faeth Therapeutics To Present Translational Data And Pharmacokinetic/Pharmacodynamic Analysis For PIKTOR, Oral Combination Of Serabelisib And Sapanisertib, At 2026 Summit For STOP Cancer

Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates

Faeth Therapeutics Q2 EPS $(2.84) Beats $(3.29) Estimate

Raymond James Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $56

Oppenheimer Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $60

Citizens Initiates Coverage On Faeth Therapeutics with Market Outperform Rating, Announces Price Target of $51

BTIG Reiterates Buy on Faeth Therapeutics, Maintains $55 Price Target

Baird Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $57

Sensei Biotherapeutics Changes Corporate Name To Faeth Therapeutics, Ticker To FTH, Effective June 16; Appoints Anand Parikh Chairman, President And CEO; Brian Stephenson Appointed CFO, Effective June 12

BTIG Initiates Coverage On Sensei Biotherapeutics with Buy Rating, Announces Price Target of $55

Cantor Fitzgerald Initiates Coverage On Sensei Biotherapeutics with Overweight Rating

LUCID CAPITAL MARKETS Initiates Coverage On Sensei Biotherapeutics with Buy Rating, Announces Price Target of $50